Wedbush Predicts Weaker Earnings for Keros Therapeutics

Keros Therapeutics, Inc. (NASDAQ:KROS) – Research analysts at Wedbush cut their FY2024 EPS estimates for shares of Keros Therapeutics in a note issued to investors on Thursday, November 7th. Wedbush analyst Y. Zhong now forecasts that the company will post earnings of ($5.29) per share for the year, down from their previous forecast of ($5.14). Wedbush currently has a “Outperform” rating and a $84.00 target price on the stock. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($5.14) per share. Wedbush also issued estimates for Keros Therapeutics’ Q4 2024 earnings at ($1.40) EPS, Q1 2025 earnings at ($1.44) EPS, Q2 2025 earnings at ($1.46) EPS, Q3 2025 earnings at ($1.34) EPS, Q4 2025 earnings at ($1.36) EPS, FY2025 earnings at ($5.58) EPS, FY2026 earnings at ($5.54) EPS, FY2027 earnings at ($5.73) EPS and FY2028 earnings at ($4.73) EPS.

Other analysts have also recently issued reports about the stock. Bank of America decreased their price target on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research report on Thursday, September 12th. Guggenheim initiated coverage on shares of Keros Therapeutics in a research report on Monday, September 23rd. They set a “buy” rating and a $96.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price target on shares of Keros Therapeutics in a research report on Thursday, November 7th. Cantor Fitzgerald initiated coverage on shares of Keros Therapeutics in a research report on Thursday, October 24th. They set an “overweight” rating for the company. Finally, Jefferies Financial Group assumed coverage on shares of Keros Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating for the company. Twelve analysts have rated the stock with a buy rating, According to MarketBeat.com, Keros Therapeutics has an average rating of “Buy” and an average target price of $88.89.

Keros Therapeutics Trading Down 4.8 %

Shares of Keros Therapeutics stock opened at $64.88 on Monday. The company has a fifty day moving average price of $58.65 and a 200 day moving average price of $52.23. Keros Therapeutics has a twelve month low of $27.31 and a twelve month high of $73.00. The stock has a market cap of $2.43 billion, a price-to-earnings ratio of -13.08 and a beta of 1.23.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company had revenue of $0.39 million for the quarter. During the same period in the previous year, the company earned ($1.33) earnings per share. The firm’s revenue for the quarter was up 4750.0% on a year-over-year basis.

Institutional Investors Weigh In On Keros Therapeutics

A number of institutional investors have recently modified their holdings of KROS. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Keros Therapeutics by 1.9% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,149 shares of the company’s stock valued at $870,000 after purchasing an additional 251 shares in the last quarter. GSA Capital Partners LLP raised its stake in shares of Keros Therapeutics by 25.5% in the 1st quarter. GSA Capital Partners LLP now owns 8,538 shares of the company’s stock valued at $565,000 after purchasing an additional 1,736 shares in the last quarter. Swiss National Bank raised its stake in shares of Keros Therapeutics by 22.0% in the 1st quarter. Swiss National Bank now owns 49,900 shares of the company’s stock valued at $3,303,000 after purchasing an additional 9,000 shares in the last quarter. ProShare Advisors LLC raised its stake in shares of Keros Therapeutics by 26.5% in the 1st quarter. ProShare Advisors LLC now owns 7,136 shares of the company’s stock valued at $472,000 after purchasing an additional 1,496 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Keros Therapeutics by 7.9% in the 1st quarter. Vanguard Group Inc. now owns 1,545,758 shares of the company’s stock valued at $102,329,000 after purchasing an additional 113,563 shares in the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.